The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Share News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 315.00
Bid: 315.00
Ask: 317.50
Change: -12.00 (-3.67%)
Spread: 2.50 (0.794%)
Open: 325.50
High: 329.50
Low: 315.00
Prev. Close: 327.00
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

SMALL-CAP WINNERS & LOSERS: ME Group upgrades outlook on robust demand

Mon, 14th Nov 2022 11:22

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Monday.

----------

SMALL-CAP - WINNERS

----------

ME Group International PLC, up 8.8% at 103.18 pence, 12-month range 55.70p - 119.50p. Upgrades its full-year outlook thanks to a first-half performance which came in ahead of expectations. The instant-service equipment firm notes a strong recovery across continental Europe and robust consumer demand for all its services. Revenue is now expected to be between GBP256 million and GBP262 million for the full-year year ended October 31, up from GBP257 million previously. Earnings before interest, taxation, depreciation, and amortisation is now expected between GBP82 million and GBP85 million, up from between GBP79 million and GBP84 million previously.

----------

Oxford BioMedica PLC, up 3.0% at 336.74 pence, 12-month range 276.62p - 1,526.00p. Completes the sale of its Windrush Court laboratory facility for GBP60 million, exceeding its target offer figure of GBP55 million. This, the biotechnology firm explains, strengthens its cash position to more than GBP150 million. In addition, the firm is granted an occupational leaseback of Windrush for 15 years at a rent of GBP3.5 million per year, rising to GBP4.7 million per year after five years.

----------

CT Private Equity Trust PLC, up 2.7% at 429.90 pence, 12-month range 375.51p - 520.00p. Sells a portion of its investment in the Italian funeral services of business of San Siro, part of funeral services firm HOFI Spa, and its related entities. At June 30, the firm's investment in San Siro was valued at EUR13.2 million. Firm sells its investment for GBP11.4 million, representing an uplift of GBP23.1 million, or 4.8% of the company June 30 net asset value. 25% of the total proceeds from the sale will be re-invested into a new investment in HOFI Spa, it adds.

----------

SMALL-CAP - LOSERS

----------

Ondo InsurTech PLC, down 3.3% at 7.25 pence, 12-month range 5.00p - 13.40p. In the six months ended August 31, widens its pretax loss to GBP2.1 million from GBP1.6 million the previous year. This comes as the firm books a GBP706,000 reverse acquisition expense in the period, and costs of sales rise to GBP511,000 from GBP475,000. Revenue, meanwhile, jumps to GBP1.0 million from GBP646,000 the year prior. Ondo says this revenue growth was driven by a growth in registered devices, which were up 43% against the prior year. "While today's economic situation is challenging, we are well placed to weather the storm... We are managing upward cost pressures on our hardware costs successfully, and although we have seen some cost increases, we have managed to pass these on to our customers," the firm adds.

----------

By Heather Rydings; heatherrydings@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
16 Apr 2021 09:49

BROKER RATINGS: RBC upgrades WH Smith and downgrades Dixons Carphone

BROKER RATINGS: RBC upgrades WH Smith and downgrades Dixons Carphone

Read more
15 Apr 2021 09:02

Oxford Biomedica swings to EBITDA profit

(Sharecast News) - Oxford Biomedica reported a 37% improvement in total revenues in its preliminary results on Thursday, to £87.7m.

Read more
15 Apr 2021 09:00

Oxford BioMedica annual revenue leaps on AstraZeneca vaccine deal

Oxford BioMedica annual revenue leaps on AstraZeneca vaccine deal

Read more
8 Apr 2021 16:05

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
6 Apr 2021 08:19

Oxford Biomedica signs viral vectors pact with Boehringer Ingelheim

Oxford Biomedica signs viral vectors pact with Boehringer Ingelheim

Read more
6 Apr 2021 08:08

Oxford Biomedica strikes three-year deal with Boehringer Ingelheim

(Sharecast News) - Gene and cell therapy company Oxford Biomedica has signed a new three-year development and supply agreement with Boehringer Ingelheim, it announced on Tuesday, for the manufacture and supply of various types of viral vectors.

Read more
6 Apr 2021 07:53

LONDON MARKET PRE-OPEN: Returns in store for BP shareholders

LONDON MARKET PRE-OPEN: Returns in store for BP shareholders

Read more
21 Mar 2021 20:57

EU rebuffs UK calls to ship AstraZeneca COVID vaccines from Europe

By Francesco GuarascioBRUSSELS, March 21 (Reuters) - The European Union is rebuffing British government calls to ship AstraZeneca COVID-19 vaccines produced in a factory in the Netherlands, an EU official said on Sunday.Former EU member Britain ha...

Read more
19 Mar 2021 10:29

Sanofi to terminate haemophilia development pact with Oxford Biomedica

Sanofi to terminate haemophilia development pact with Oxford Biomedica

Read more
19 Mar 2021 07:50

Oxford Biomedica says Sanofi pulling out of haemophilia project

(Sharecast News) - Oxford Biomedica said that Sanofi's decision to terminate collaboration on a haemophilia treatment would have a "negligible" impact on revenue.

Read more
3 Feb 2021 13:56

IN BRIEF: Oxford Biomedica Adds Genetics Professor To Non-Exec Team

IN BRIEF: Oxford Biomedica Adds Genetics Professor To Non-Exec Team

Read more
29 Jan 2021 09:11

UPDATE 1-EU holds out for more after AstraZeneca offered 8 mln extra COVID-19 shots

* Astra had committed to at least 80 mln shots in Q1* EU funded two UK plants under deal with Astra - sources* Astra says UK has priority for doses produced there (Adds detail, background)By Francesco Guarascio and Sabine SieboldBRUSSELS, Jan 29 (Re...

Read more
18 Jan 2021 17:18

IN BRIEF: Oxford Biomedica's Facility In Oxford Now Formally Opened

IN BRIEF: Oxford Biomedica's Facility In Oxford Now Formally Opened

Read more
8 Jan 2021 09:40

UK BROKER RATINGS SUMMARY: Shore Says Buy Hargreaves; UBS Cuts Next

UK BROKER RATINGS SUMMARY: Shore Says Buy Hargreaves; UBS Cuts Next

Read more
8 Dec 2020 12:31

UK's initial AstraZeneca shots will come from Europe, taskforce says

By Alistair SmoutLONDON, Dec 8 (Reuters) - Britain's initial doses of the COVID-19 vaccine candidate developed by AstraZeneca and Oxford University will come from Europe rather than a domestic supply chain, the country's Vaccine Taskforce said.The...

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.